Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in 11C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer

Molecular Imaging and Biology

Volumn 13, Issue 2, 2011, Pages 352-361

  Beer, Ambros J ^a   Eiber, Matthias ^a   Souvatzoglou, Michael ^a   Holzapfel, Konstantin ^a   Ganter, Carl ^a   Weirich, Gregor ^a   Maurer, Tobias ^a   Kübler, Hubert ^a   Wester, Hans Juergen ^a   Gaa, Jochen ^a   Krause, Bernd J ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

11C choline PET CT; Comparison; Diffusion weighted MR imaging; Lymph node metastases; Prostate cancer

Indexed keywords

CHOLINE C 11;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DISPERSION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MALE; PELVIS LYMPH NODE; PERFORMANCE; PRIORITY JOURNAL; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RESTRICTED WATER DIFFUSIBILITY; STANDARDIZED UPTAKE VALUE;

AGED; CARBON RADIOISOTOPES; CHOLINE; DIFFUSION MAGNETIC RESONANCE IMAGING; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PELVIS; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE; TOMOGRAPHY, X-RAY COMPUTED; WATER;

EID: 79955937462     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-010-0337-6     Document Type: Article

References (58)

1. Gronberg H (2003) Prostate cancer epidemiology. Lancet 361:859-864
2. Soh S, Kattan M, Berkman S, Wheeler T, Scardino P (1997) Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol 157:2212-2218
3. Cagiannos I, Karakiewicz P, Eastham J et al (2003) A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 170:1798-1803 (Pubitemid 37254931)
4. Hricak H, Schoder H, Pucar D et al (2003) Advances in imaging in the postoperative patient with a rising prostate-specific antigen level. Semin Oncol 30:616-634 (Pubitemid 37296787)
5. de Jong I, Pruim J, Elsinga P, Vaalburg W, Mensink H (2003) Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 44:331-335 (Pubitemid 39586006)
6. Rorvik J, Halvorsen O, Albrektsen G, Haukaas S (1998) Lymphangiography combined with biopsy and computer tomography to detect lymph node metastases in localized prostate cancer. Scand J Urol Nephrol 32:116-119 (Pubitemid 28206804)
7. Jager G, Barentsz J, Oosterhof G, Witjes J, Ruijs S (1996) Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence. AJR Am J Roentgenol 167:1503-1507 (Pubitemid 26418741)
8. Oyen R, Van Poppel H, Ameye F et al (1994) Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. Radiology 190:315-322 (Pubitemid 24044226)
9. Wang L, Hricak H, Kattan M et al (2006) Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. AJR Am J Roentgenol 186:743-748 (Pubitemid 46100258)
10. Wolf J, Cher M, Dall'era M et al (1995) The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol 153:993-999
11. Harisinghani M, Barentsz J, Hahn P et al (2003) Noninvasive detection of clinically occult lymph node metastases in prostate cancer. N Engl J Med 348:2491-2499 (Pubitemid 36706536)
12. Hricak H, Choyke P, Eberhardt S, Leibel S, Scardino P (2007) Imaging prostate cancer: a multidisciplinary perspective. Radiology 243:28-53 (Pubitemid 46579693)
13. Krause B, Souvatzoglou M, Tuncel M et al (2008) The detection rate of [(11)C]Choline-PET/CT depends on the serum PSA value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 35:18-23
14. Reske S, Blumstein N, Glatting G (2008) [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 35:9-17 (Pubitemid 350234137)
15. Rinnab L, Mottaghy F, Blumstein N et al (2007) Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 100:786-793
16. Husarik D, Miralbell R, Dubs M et al (2008) Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 35:253-263
17. Scattoni V, Picchio M, Suardi N et al (2007) Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 52:423-429 (Pubitemid 46963456)
18. Eschmann S, Pfannenberg A, Rieger A et al (2007) Comparison of 11C-choline-PET/CT and whole body MRI for staging of prostate cancer. Nuklearmedizin 46:161-168 (Pubitemid 47612279)
19. Yoshida S, Nakagomi K, Goto S, Futatsubashi M, Torizuka T (2005) 11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging. Urol Int 74:214-220 (Pubitemid 41201531)
20. Wesbey G, Moseley M, Ehman R (1984) Translational molecular self-diffusion in magnetic resonance imaging. II. Measurement of the self-diffusion coefficient. Invest Radiol 19:491-498
21. Koh D, Collins D (2007) Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 188:1622-1635 (Pubitemid 46866868)
22. Abdel Razek A, Soliman N, Elkhamary S, Alsharaway M, Tawfik A (2006) Role of diffusion-weighted MR imaging in cervical lymphadenopathy. Eur Radiol 16:1468-1477 (Pubitemid 43871818)
23. Holzapfel K, Duetsch S, Fauser C et al (2009) Value of diffusion-weighted MR imaging in the differentiation between benign and malignant cervical lymph nodes. Eur J Radiol 72(3):381-387
24. Kim J, Kim K, Park B, Kim N, Cho K (2008) Feasibility of diffusion-weighted imaging in the differentiation of metastatic from nonmetastatic lymph nodes: early experience. J Magn Reson Imaging 28:714-719
25. Lichy M, Aschoff P, Plathow C et al (2007) Tumor detection by diffusion-weightedMRI and ADC-mapping-initial clinical experiences in comparison to PET-CT. Invest Radiol 42:605-613 (Pubitemid 47262928)
26. Thoeny H, Triantafyllou M, Birkhaeuser F et al (2009) Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol 55(4):761-769
27. Hara T (2002) 11C-choline and 2-deoxy-2-[18F]fluoro-D-glucose in tumor imaging with positron emission tomography. Mol Imaging Biol 4:267-273
28. Klerkx W, Mali W, Peter HA et al (2009) Observer variation of magnetic resonance imaging and diffusion weighted imaging in pelvic lymph node detection. Eur J Radiol
29. Hickeson M, Yun M, Matthies A et al (2002) Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging 29:1639-1647
30. Thie J (2004) Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 45:1431-1434
31. Soret M, Bacharach S, Buvat I (2007) Partial-volume effect in PET tumor imaging. J Nucl Med 48:932-945 (Pubitemid 46909922)
32. Tuncel M, Souvatzoglou M, Herrmann K et al (2008) [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. Nucl Med Biol 35:689-695
33. Bruegel M, Holzapfel K, Gaa J et al (2008) Characterization of focal liver lesions by ADC measurements using a respiratory triggered diffusion-weighted single-shot echo-planar MR imaging technique. Eur Radiol 18:477-485 (Pubitemid 351248179)
34. Holzapfel K, Bruegel M, Eiber M et al (2009) Characterization of small (
35. Low R, Gurney J (2007) Diffusion-weighted MRI (DWI) in the oncology patient: value of breathhold DWI compared to unenhanced and gadolinium-enhanced MRI. J Magn Reson Imaging 25:848-858 (Pubitemid 46516739)
36. Shen S, Chiou Y, Wang J et al (2008) Diffusion-weighted single-shot echo-planar imaging with parallel technique in assessment of endometrial cancer. AJR Am J Roentgenol 190:481-488 (Pubitemid 351196621)
37. Ho K, Lin G, Wang J et al (2008) Correlation of apparent diffusion coefficients measured by 3T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer. Eur J Nucl Med Mol Imaging 35:493-501
38. Mori T, Nomori H, Ikeda K et al (2008) Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography. J Thorac Oncol 3:358-364 (Pubitemid 351489475)
39. Palumbo B, Angotti F, Marano G (2008) Relationship between PET-FDG and MRI apparent diffusion coefficients in brain tumors. Q J Nucl Med Mol Imaging 53(1):17-22
40. Ackerstaff E, Pflug B, Nelson J, Bhujwalla Z (2001) Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 61:3599-3603 (Pubitemid 32694969)
41. Casciani E, Gualdi G (2006) Prostate cancer: value of magnetic resonance spectroscopy 3D chemical shift imaging. Abdom Imaging 31:490-499 (Pubitemid 46352054)
42. Ramirez DM, Gutierrez R, Ramos M et al (2002) Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene 21:4317-4322 (Pubitemid 34753838)
43. Ramirez DM, Rodriguez-Gonzalez A, Gutierrez R et al (2002) Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 296:580-583
44. Hara T, Bansal A, Degrado T (2006) Choline transporter as a novel target for molecular imaging of cancer. Mol Imaging 5:498-509 (Pubitemid 46142823)
45. Katz-Brull R, Degani H (1996) Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res 16:1375-1380
46. Provenzale J, Mukundan S, Barboriak D (2006) Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology 239:632-649 (Pubitemid 43830599)
47. Wang J, Takashima S, Takayama F et al (2001) Head and neck lesions: characterization with diffusion-weighted echo-planar MR imaging. Radiology 220:621-630 (Pubitemid 32799967)
48. Hofer C, Laubenbacher C, Block T et al (1999) Fluorine-18- fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 36:31-35 (Pubitemid 29265277)
49. Nuñez R, Macapinlac HA, Yeung HWD et al (2002) Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 43:46-55 (Pubitemid 34101187)
50. Morris MJ, Akhurst T, Osman I et al (2002) Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 59:913-918 (Pubitemid 34522186)
51. Agus DB, Golde DW, Sgouros G et al (1998) Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer Res 58:3009-3014 (Pubitemid 28335080)
52. Picchio M, Crivellaro C, Giovacchini G, Gianolli L, Messa C (2009) PET-CT for treatment planning in prostate cancer. The Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical. Chemistry and Biology 53:245-268
53. Torizuka T, Kanno T, Futatsubashi M et al (2003) Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 44:1051-1056 (Pubitemid 39663379)
54. Wyss M, Weber B, Honer M et al (2004) 18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET. Eur J Nucl Med Mol Imaging 31:312-316 (Pubitemid 38314073)
55. van Waarde A, Jager P, Ishiwata K, Dierckx R, Elsinga P (2006) Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation. J Nucl Med 47:150-154 (Pubitemid 46768524)
56. Sutinen E, Nurmi M, Roivainen A et al (2004) Kinetics of [(11)C] choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 31:317-324
57. Farsad M, Schiavina R, Castellucci P et al (2005) Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 46:1642-1649 (Pubitemid 46211588)
58. Heesakkers R, Hovels A, Jager G et al (2008) MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 9:850-856